Dow Jones
38.852,27 +176,59 (+0,46%) Nasdaq
16.349,25 +192,92 (+1,19%) Nikkei 225
38.668,11 +432,04 (+1,13%) EUR/USD
1,0767 -0,0007 (-0,06%) Bitcoin EUR
59.260,49 -363,43 (-0,61%) CMC Crypto 200
1.371,81 +59,18 (+4,51%)
INCY May 2024 60.000 put
| Chiusura precedente | 5,0000 |
| Aperto | 5,0000 |
| Denaro | 4,6000 |
| Lettera | 8,3000 |
| Prezzo d'esercizio | 60,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 5,0000 - 5,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 3 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
